Lakefront Biotherapeutics NV (NASDAQ:LKFT) — Market Cap & Net Worth
Market Cap & Net Worth: Lakefront Biotherapeutics NV (LKFT)
Lakefront Biotherapeutics NV (NASDAQ:LKFT) has a market capitalization of $1.76 Billion ($1.76 Billion) as of October 10, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6557 globally and #2053 in its home market, demonstrating a -6.94% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lakefront Biotherapeutics NV's stock price $26.81 by its total outstanding shares 65484670 (65.48 Million).
Lakefront Biotherapeutics NV Market Cap History: 2026 to 2026
Lakefront Biotherapeutics NV's market capitalization history from 2026 to 2026. Data shows growth from $1.93 Billion to $1.93 Billion (0.00% CAGR). Check Lakefront Biotherapeutics NV (LKFT) share price today for real-time trading data and today's change.
Lakefront Biotherapeutics NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lakefront Biotherapeutics NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see LKFT cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LKFT by Market Capitalization
Companies near Lakefront Biotherapeutics NV in the global market cap rankings as of October 10, 2026. See debt-free asset ratio of Lakefront Biotherapeutics NV to understand what proportion of total assets are financed by equity.
Key companies related to Lakefront Biotherapeutics NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $127.55 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $74.80 Billion USD.
- CSL Ltd (AU:CSL): Ranked #450 globally with a market cap of $62.29 Billion USD ( AU$88.04 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $127.55 Billion | $503.25 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $739.57 |
| #450 | CSL Ltd | AU:CSL | $62.29 Billion | AU$181.46 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $197.00 |
Lakefront Biotherapeutics NV Historical Marketcap From 2026 to 2026
Between 2026 and today, Lakefront Biotherapeutics NV's market cap moved from $1.93 Billion to $ 1.93 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.93 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 12th, 2026 the market cap of Lakefront Biotherapeutics NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.76 Billion USD |
| MoneyControl | $1.76 Billion USD |
| MarketWatch | $1.76 Billion USD |
| marketcap.company | $1.76 Billion USD |
| Reuters | $1.76 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in… Read more